Search - tctmd.com

Displaying 181 - 200 of 267

Sort: Relevancy | Date

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

Yael L. Maxwell

April 09, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Caitlin E. Cox

January 24, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Bullying or Violence on the Job May Boost CVD Risk

Todd Neale

November 22, 2018

News Daily News

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Caitlin E. Cox

November 21, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Advertisement

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Top News in Clinical Cardiology: 2018

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Bullying or Violence on the Job May Boost CVD Risk

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content